共 50 条
- [1] Pembrolizumab in Triple-Negative Breast Cancer [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (15): : 1435 - 1435
- [2] Pembrolizumab for Early Triple-Negative Breast Cancer [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (09): : 810 - 821
- [4] Pembrolizumab in Early Triple-Negative Breast Cancer [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (18): : 1771 - 1771
- [5] Pembrolizumab and atezolizumab in triple-negative breast cancer [J]. Cancer Immunology, Immunotherapy, 2021, 70 : 607 - 617
- [6] Pembrolizumab for Early Triple-Negative Breast Cancer [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (26):
- [7] Pembrolizumab in Triple-Negative Breast Cancer Reply [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (15): : 1436 - 1436
- [8] Pembrolizumab monotherapy in metastatic triple-negative breast cancer [J]. LANCET ONCOLOGY, 2021, 22 (04): : 415 - 417
- [10] Pembrolizumab for Early Triple-Negative Breast Cancer Reply [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (26):